Five things for pharma marketers to know: Wednesday, October 4, 2017

Share this content:


1. The FDA approved Mylan's generic version of Teva Pharmaceutical Industries' multiple sclerosis drug Copaxone. Novartis and Momenta Pharmaceuticals also sell generic versions of Copaxone. (Reuters)

2. Three out of every 1,000 Americans had a bill of more than $50,000 a year in prescription drug costs, according to an Express Scripts' analysis of its health plan members. (BioPharmaDIVE)

3. Some health insurers participating in the health exchanges will raise premiums by more than 50% next year. (NYT)

4. FDA commissioner Scott Gottlieb told Congress that the agency may start investigating health claims companies make about marijuana. “I think we do bear some responsibility to start to address these questions,” Gottlieb said. (Bloomberg)

5. ICYMI: Sanofi and Aetna announced a pilot to study the impact of digital health in type 2 diabetes patients. The study will use a diabetes self-management app and a Bluetooth-activated blood sugar monitor, and it will analyze if using those tools improves adherence and outcomes. (MobiHealthNews)

Share this content:
Scroll down to see the next article